Major Medicare Advantage and Part D Changes Effective Jan 2025
As of January 2025, Medicare Advantage plans are undergoing significant changes that will impact beneficiaries and allow for improved access and affordability. Below is an overview of these key updates and implications:
Elimination of the Coverage Gap
The Coverage Gap Discount Program, which provides discounts to eligible Medicare beneficiaries for brand-name drugs, was disbanded on Jan 1, 2025. It has been replaced by the Manufacturer Discount Program (MDP), which pays a 10% discount for brand-name drugs in the initial coverage phase and 20% in the catastrophic phase.
One point to note – discounts under the CGDP were applied to the negotiated price of the drug excluding dispensing fees. However, for the MDP, discounts are applied to the total negotiated price of the drug, including the dispensing fee.

Source: From Coverage Gap to Member Cap, Wakely 2024
The Effects of MDP
The implications of MDP for manufacturers and plan sponsors are:
- For plan sponsors, claims systems must incorporate these discount rules for specific drugs, dosage forms, and member-cost share adjustments. Also, accurate reconciliation with manufacturer contracts adds layers to the post-adjudication process.
- Eligibility checks and coordination with PBMs and manufacturers are essential for validating discounts, potentially slowing adjudication. This requires seamless integration with external databases to ensure accurate application.
- Manufacturers may see their Part D claim discount liabilities increase for high-cost members, since they now have unlimited liability in the catastrophic coverage phase
Monthly Premiums Option
In 2025, the average monthly premium for Medicare Advantage plans is projected to decrease by 6.75%, from $18.23 in 2024 to $17.00 in 2025. Moreover, the enrollment in MA is projected at 35.7M in 2025, constituting 51% of all members enrolled in Medicare.
Also, the Inflation Reduction Act will cap out-of-pocket drug costs to $2,000 annually. This cost cap, combined with the new option to spread out-of-pocket prescription drug costs across the year, offers beneficiaries more financial flexibility and predictability.
Broader Focus on Supplemental Benefits
A significant change for Medicare Advantage in 2025 is the emphasis on supplemental benefits that go beyond standard medical care. Many plans are now including services like transportation for non-emergency medical appointments and meal deliveries for those with chronic illnesses.
These enhancements aim to improve access to care while addressing broader health barriers. For payers, this shift introduces new complexities in claims processing and eligibility verification, highlighting the importance of scalable systems and automation to efficiently manage the variety of services.
Updated NCCI Policy Manual and Improved Star Ratings Incentives
Starting January 1, 2025, the Medicaid National Correct Coding Initiative Policy Manual introduces updated guidelines aimed at reducing coding errors and preventing improper payments. While these updates primarily target Medicaid services, they carry significant implications for payers managing dual-eligible beneficiaries enrolled in both Medicare Advantage and Medicaid.
Also, changes have been made to the CMS Star Ratings, which evaluate plans based on factors like member experience, preventive services, and health outcomes. These changes have mostly been minor including, increasing the weight for Part C Plan All-Cause Readmissions.
Conclusion
In summary, the changes to Medicare Advantage and Part D programs effective January 2025 represent a major shift toward affordability, access, and enhanced care for beneficiaries. While these updates introduce new benefits and cost-saving measures, they also require payers and manufacturers to adapt their systems and processes to meet evolving regulatory and operational demands.
Please reach out to the Mizzeto team if you’d like to learn more about how health plans and TPAs can operationalize these changes.